Incyte Corp. (INCY)

78.42
NASDAQ : Health Technology
Prev Close 78.67
Day Low/High 77.93 / 79.50
52 Wk Low/High 57.00 / 96.44
Avg Volume 1.64M
Exchange NASDAQ
Shares Outstanding 212.81M
Market Cap 16.74B
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Incyte Appoints Christiana Stamoulis As Chief Financial Officer

Incyte Appoints Christiana Stamoulis As Chief Financial Officer

Incyte (Nasdaq:INCY) today announced the appointment of Christiana Stamoulis as Executive Vice President and Chief Financial Officer, effective February 11, 2019.

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program For Ruxolitinib Cream In Atopic Dermatitis

Incyte Announces First Patient Treated In Phase 3 Clinical Trial Program For Ruxolitinib Cream In Atopic Dermatitis

Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating the long-term safety and efficacy of ruxolitinib cream as monotherapy for adolescent and adult patients (age ≥ 12 years)...

Http://innoventbio.com/en/

Http://innoventbio.com/en/

Incyte (NASDAQ:INCY) and Innovent Biologics, Inc. (Innovent) (HKEX: 01801) today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates...

Innovent And Incyte Announce Strategic Collaboration And Licensing Agreement For Three Clinical-stage Product Candidates In China

Innovent And Incyte Announce Strategic Collaboration And Licensing Agreement For Three Clinical-stage Product Candidates In China

SUZHOU, China, Dec. 16, 2018 /PRNewswire/ -- Innovent Biologics, Inc.

Incyte To Present At Upcoming Investor Conferences

Incyte To Present At Upcoming Investor Conferences

Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of January: Goldman Sachs 11 th Annual Healthcare CEOs Unscripted: A View from the Top Conference on Thursday, January 3, 2019 at...

FDA Grants Fast Track Designation To The Baricitinib Development Program For The Treatment Of Systemic Lupus Erythematosus (SLE)

FDA Grants Fast Track Designation To The Baricitinib Development Program For The Treatment Of Systemic Lupus Erythematosus (SLE)

INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.

Results Of REACH1 Study Of Ruxolitinib (Jakafi®) For The Treatment Of Acute Graft-Versus-Host Disease Demonstrate Rapid And Durable Patient Benefit

Results Of REACH1 Study Of Ruxolitinib (Jakafi®) For The Treatment Of Acute Graft-Versus-Host Disease Demonstrate Rapid And Durable Patient Benefit

Incyte Corporation (Nasdaq:INCY) announces updated results from its pivotal Phase 2 REACH1 study evaluating ruxolitinib (Jakafi ®) in combination with corticosteroids as a treatment for patients with acute graft-versus-host disease (GVHD) who have had an...

Incyte Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Twenty-First Century Fox

Incyte Becomes #29 Most Shorted Nasdaq 100 Component, Replacing Twenty-First Century Fox

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte Appoints Dr. Dashyant Dhanak As Chief Scientific Officer

Incyte Appoints Dr. Dashyant Dhanak As Chief Scientific Officer

Incyte (NASDAQ:INCY) today announced the appointment of Dashyant Dhanak, Ph.D.

Incyte To Present At Upcoming Investor Conference

Incyte To Present At Upcoming Investor Conference

Incyte Corporation (Nasdaq:INCY) announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.

Multiple Abstracts Highlighting Data From Incyte's Targeted Therapy Portfolio Accepted For Presentation At The 60th Annual ASH Meeting

Multiple Abstracts Highlighting Data From Incyte's Targeted Therapy Portfolio Accepted For Presentation At The 60th Annual ASH Meeting

Incyte (Nasdaq:INCY) announces that multiple abstracts, including data from its clinical development programs for ruxolitinib (Jakafi ®), pemigatinib and INCB50465 will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2018...

Incyte Reports 2018 Third Quarter And Nine Month Financial Results And Provides Updates On Key Clinical Programs

Incyte Reports 2018 Third Quarter And Nine Month Financial Results And Provides Updates On Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 third quarter and nine month financial results and provides a status update on the Company's development portfolio.

Incyte Named A 2018 Top Employer By Science Magazine

Incyte Named A 2018 Top Employer By Science Magazine

Incyte Corporation (Nasdaq:INCY) announced today that it has been named one of the global biotechnology and pharmaceutical industry's top employers by Science magazine, ranking second on the list of only 20 companies recognized in the publication's annual...

FDA Grants Priority Review For Ruxolitinib (Jakafi®) As A Treatment For Patients With Acute Graft-Versus-Host Disease

FDA Grants Priority Review For Ruxolitinib (Jakafi®) As A Treatment For Patients With Acute Graft-Versus-Host Disease

Incyte Corporation (Nasdaq:INCY) today announced that the U.S.

ACR 2018: Lilly Shares Updated Safety Analysis Of OLUMIANT® (baricitinib) In Patients With Moderately-to-Severely Active Rheumatoid Arthritis

ACR 2018: Lilly Shares Updated Safety Analysis Of OLUMIANT® (baricitinib) In Patients With Moderately-to-Severely Active Rheumatoid Arthritis

- Integrated safety analysis reflects long-term results from 3,492 treated patients for 7,860 patient-years of exposure -

Incyte Announces Positive Interim Data From Phase 2 Trial Of Pemigatinib, Its Selective FGFR Inhibitor, In Patients With Cholangiocarcinoma

Incyte Announces Positive Interim Data From Phase 2 Trial Of Pemigatinib, Its Selective FGFR Inhibitor, In Patients With Cholangiocarcinoma

Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically...

Phase 2 GEOMETRY Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results In Patients With MET-mutated Advanced NSCLC

Phase 2 GEOMETRY Mono-1 Trial Of Investigational Medicine Capmatinib Shows Positive Results In Patients With MET-mutated Advanced NSCLC

Incyte (NASDAQ:INCY) today announced Phase 2 preliminary results of the GEOMETRY mono-1 clinical trial of investigational MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping...

Today's Market Had Something for Everyone

In the end the market closed flat as a pancake.

Incyte To Report Third Quarter Financial Results

Incyte To Report Third Quarter Financial Results

Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled its third quarter 2018 financial results conference call and webcast for 8:00 a.

Incyte Becomes #24 Most Shorted Nasdaq 100 Component, Replacing Hologic

Incyte Becomes #24 Most Shorted Nasdaq 100 Component, Replacing Hologic

The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Incyte Announces Data For Pemigatinib, Its Selective FGFR Inhibitor, To Be Featured At The ESMO 2018 Congress

Incyte Announces Data For Pemigatinib, Its Selective FGFR Inhibitor, To Be Featured At The ESMO 2018 Congress

Incyte (Nasdaq:INCY) announces that interim Phase 2 data on its investigational, selective FGFR1/2/3 inhibitor, pemigatinib (INCB54828), will be presented at the upcoming European Society for Medical Oncology (ESMO) 2018 Congress taking place in Munich,...

Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline

Tesla, Facebook, Amazon and Netflix Lead the Nasdaq's Sharp Decline

The Nasdaq is down more than 2% on Thursday as tech shares sink.

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

Incyte Becomes #35 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

The most recent short interest data has been released for the 08/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Film Showcasing Four Unique MPN Stories.

Film Showcasing Four Unique MPN Stories.

Today on MPN Awareness Day and throughout September, Blood Cancer Awareness Month, Incyte Corporation (Nasdaq:INCY) is shining a light on myeloproliferative neoplasms (MPNs).

Incyte Announces Positive Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis

Incyte Announces Positive Data From Phase 2b Trial Of Ruxolitinib Cream In Patients With Atopic Dermatitis

Incyte Corporation (Nasdaq:INCY) today announced positive results from its randomized, dose-ranging, vehicle- and active-controlled Phase 2b study evaluating ruxolitinib cream in patients with atopic dermatitis (AD) who are candidates for topical therapy.

Foundation Medicine

Foundation Medicine

Incyte Corporation (NASDAQ:INCY) and Foundation Medicine, Inc., today announced that the companies have entered into an agreement for the development, regulatory support and commercialization of companion diagnostics (CDx), with an initial focus on CDx...

Incyte Announces Chief Financial Officer David Gryska To Retire At The End Of 2018

Incyte Announces Chief Financial Officer David Gryska To Retire At The End Of 2018

Incyte Corporation (Nasdaq:INCY) today announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement.

TheStreet Quant Rating: D+ (Sell)